FDA Extends Review of Capricor’s Duchenne Muscular Dystrophy Cell Therapy

By Dr. Zubair Khalid, DVM, MS, PhD ·

FDA Extends Review of Capricor’s Duchenne Muscular Dystrophy Cell Therapy

Key Takeaways

  • The U.S. Food and Drug Administration (FDA) has extended its review period for Capricor Therapeutics' experimental cell therapy intended for Duchenne muscular dystrophy (DMD). This extension delays a final regulatory decision beyond the original target date.
  • The FDA's decision follows a negative vote from its advisory committee, which had expressed concerns regarding the therapy's efficacy and safety profile. Capricor subsequently submitted new data for evaluation.
  • Capricor's investigational therapy uses donor-derived cardiac cells, engineered to deliver a therapeutic protein directly to affected muscle tissue, aiming to mitigate the progressive muscle degeneration characteristic of DMD.
  • Duchenne muscular dystrophy is a severe genetic disorder affecting approximately 1 in 3,500 male births, caused by mutations in the dystrophin gene, leading to progressive muscle wasting and premature mortality.
  • The extended review underscores the complex regulatory pathway for cell-based therapies, requiring robust demonstration of consistent manufacturing processes and sustained clinical benefit, particularly for rare genetic diseases.

The U.S. Food and Drug Administration has extended its review of Capricor Therapeutics’ experimental cell therapy for Duchenne muscular dystrophy (DMD), delaying a final decision. The agency requested additional time to evaluate information the biotech submitted after an advisory committee voted against the drug candidate.

Capricor announced the extension, which pushes the FDA’s action date beyond the original deadline. The company had submitted the new data following a negative vote from the agency’s advisory panel, which raised concerns about the therapy’s efficacy and safety profile.

The FDA’s decision to extend the review, rather than issue a complete response letter or approve the drug, gives Capricor a temporary reprieve. The biotech now awaits a final ruling on its cell therapy, which is designed to slow disease progression in boys with DMD, a severe genetic muscle-wasting condition.

Context

Duchenne muscular dystrophy affects approximately one in every 3,500 male births worldwide. It is caused by mutations in the dystrophin gene, leading to progressive muscle degeneration and premature death. Current treatments include corticosteroids and gene therapies, but no cure exists. Capricor’s approach uses donor-derived heart cells to deliver a therapeutic protein directly to muscle tissue. The FDA’s extended review highlights the regulatory challenges facing cell-based therapies, which must demonstrate consistent manufacturing and durable clinical benefit. A positive decision could open a new treatment pathway for DMD patients, while a negative outcome would set back the field of cell therapy for rare genetic diseases.

Source: original report